112 related articles for article (PubMed ID: 33567813)
1. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia.
Mateos MK; Marshall GM; Barbaro PM; Quinn MCJ; George C; Mayoh C; Sutton R; Revesz T; Giles JE; Barbaric D; Alvaro F; Mechinaud F; Catchpoole D; Lawson JA; Chenevix-Trench G; MacGregor S; Kotecha RS; Dalla-Pozza L; Trahair TN
Haematologica; 2022 Mar; 107(3):635-643. PubMed ID: 33567813
[TBL] [Abstract][Full Text] [Related]
2. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate.
Harris RD; Bernhardt MB; Zobeck MC; Taylor OA; Gramatges MM; Schafer ES; Lupo PJ; Rabin KR; Scheurer ME; Brown AL
Cancer; 2023 Apr; 129(8):1287-1294. PubMed ID: 36692972
[TBL] [Abstract][Full Text] [Related]
3. Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
Rupakumar T; Sankar A; Vijayasekharan K; Varikkattu Rajendran P; Chellapan Sojamani G; Rajeswari B; Nair M; Anandarajan R; Dennis D; Thankamony P
Br J Haematol; 2024 May; ():. PubMed ID: 38797523
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia.
Richards S; Pui CH; Gayon P;
Pediatr Blood Cancer; 2013 Feb; 60(2):185-95. PubMed ID: 22693038
[TBL] [Abstract][Full Text] [Related]
5. Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.
Akimoto M; Miyazaki T; Takahashi H; Saigusa Y; Takeda T; Hibino Y; Tokunaga M; Ohashi T; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Matsumoto K; Hashimoto C; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Nakajima H
Int J Hematol; 2024 Feb; 119(2):164-172. PubMed ID: 38233702
[TBL] [Abstract][Full Text] [Related]
6. Clinico-radiological profile, management and follow-up of methotrexate induced neurotoxicity in children with acute lymphoblastic leukemia.
Dhariwal N; Roy Moulik N; Smriti V; Dhamne C; Chichra A; Srinivasan S; Narula G; Banavali S
Leuk Lymphoma; 2023 Dec; 64(12):1971-1980. PubMed ID: 37565568
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Gut Microbiota Changes on Methotrexate-Induced Neurotoxicity in Developing Young Rats.
Chen YC; Hou CY; Hsu MH; Huang LT; Hsiao CC; Sheen JM
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672262
[TBL] [Abstract][Full Text] [Related]
8. Cumulative Dosage of Intrathecal Chemotherapy Agents Predicts White Matter Integrity in Long-Term Survivors of Acute Lymphoblastic Leukemia: A PETALE Study.
Laniel J; Sultan S; Sinnett D; Laverdière C; Krajinovic M; Robaey P; Duong L; Lippé S
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539543
[TBL] [Abstract][Full Text] [Related]
9. Characterization of brain development with neuroimaging in a female mouse model of chemotherapy treatment of acute lymphoblastic leukemia.
Gandy K; Koscik TR; Alexander T; Steinberg JD; Krull KR; van der Plas E
Transl Pediatr; 2024 Mar; 13(3):408-416. PubMed ID: 38590373
[TBL] [Abstract][Full Text] [Related]
10. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome.
Winter G; Kirschner-Schwabe R; Groeneveld-Krentz S; Escherich G; Möricke A; von Stackelberg A; Stanulla M; Bailey S; Richter L; Steinemann D; Ripperger T; Escudero A; Farah R; Lohi O; Wadt K; Jongmans M; van Engelen N; Eckert C; Kratz CP
Leukemia; 2021 May; 35(5):1475-1479. PubMed ID: 33580201
[No Abstract] [Full Text] [Related]
11. Immune function in childhood cancer survivors: a Children's Oncology Group review.
Guilcher GMT; Rivard L; Huang JT; Wright NAM; Anderson L; Eissa H; Pelletier W; Ramachandran S; Schechter T; Shah AJ; Wong K; Chow EJ
Lancet Child Adolesc Health; 2021 Apr; 5(4):284-294. PubMed ID: 33600774
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
[TBL] [Abstract][Full Text] [Related]
13. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
[TBL] [Abstract][Full Text] [Related]
14. GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma.
Dong Z; Yeo KS; Lopez G; Zhang C; Dankert Eggum EN; Rokita JL; Ung CY; Levee TM; Her ZP; Howe CJ; Hou X; van Ree JH; Li S; He S; Tao T; Fritchie K; Torres-Mora J; Lehman JS; Meves A; Razidlo GL; Rathi KS; Weroha SJ; Look AT; van Deursen JM; Li H; Westendorf JJ; Maris JM; Zhu S
Cancer Res; 2021 Jun; 81(11):2995-3007. PubMed ID: 33602789
[TBL] [Abstract][Full Text] [Related]
15. Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment.
Coorens THH; Collord G; Lu W; Mitchell E; Ijaz J; Roberts T; Oliver TRW; Burke GAA; Gattens M; Dickens E; Nangalia J; Tischkowitz M; Anderson J; Shlien A; Godfrey AL; Murray MJ; Behjati S
Blood; 2021 May; 137(21):2992-2997. PubMed ID: 33598691
[No Abstract] [Full Text] [Related]
16. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
Tsaur G; Popov A; Riger T; Kustanovich A; Solodovnikov A; Shorikov E; Demina A; Verzhbitskaya T; Streneva O; Makarova O; Lapotentova E; Aleinikova O; Miakova N; Boichenko E; Kondratchik K; Ponomareva N; Karachunskiy A; Roumiantsev A; Fechina L
Br J Haematol; 2021 Jun; 193(6):1151-1156. PubMed ID: 33583020
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
18. Acute Leukemia in Infants.
Ibrahimova A; Pommert L; Breese EH
Curr Oncol Rep; 2021 Feb; 23(3):27. PubMed ID: 33580326
[TBL] [Abstract][Full Text] [Related]
19. Low CtBP2 expression is associated with a stem cell-like signature and adverse clinical outcome in childhood B-cell lymphoblastic leukemia.
Chun S; Kim HY; Kim HJ; Koo HH; Yoo KH; Kim SH; Zhou M; Lee ST; Wiemels JL
Leukemia; 2021 Sep; 35(9):2684-2687. PubMed ID: 33580202
[No Abstract] [Full Text] [Related]
20. Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas.
Khan A; Gamble LD; Upton DH; Ung C; Yu DMT; Ehteda A; Pandher R; Mayoh C; Hébert S; Jabado N; Kleinman CL; Burns MR; Norris MD; Haber M; Tsoli M; Ziegler DS
Nat Commun; 2021 Feb; 12(1):971. PubMed ID: 33579942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
